Stathmin overexpression in aggressive endometrial cancer -5 -Endometrial cancer is the most common gynecological malignancy in the western world and the incidence is rising in several countries (1). 15-20% of patients with presumed localized disease at primary treatment recur (2, 3) . Although metastatic lymph nodes detected as part of the surgical staging procedure identifies patients with poor prognosis, the procedure has been associated with higher complication rates (4) . Routine pelvic lymph node sampling has not confirmed to contribute to a survival benefit for the patients subjected to such (4, 5) .
We are still in need of better prognosticators to tailor treatment for high-risk groups.
Identification of new reliable molecular markers in preoperative curettage specimens would contribute to such individualized surgical and adjuvant treatment.
The oncoprotein Stathmin is known to be a microtubule destabilisator, promoting cell proliferation, mobility, metastasis and resistance to antimicrotubule therapy (6, 7) .
Immunohistochemical staining has demonstrated Stathmin protein expression to be correlated with aggressive clinico-pathological variables and poor prognosis in endometrial cancer (8) and several other malignancies such as breast (9, 10) , ovarian (11) and cervical cancer (12) .
The PI3Kinase signaling pathway is one of the major oncogenic pathways found to be upregulated in cancer in general, and in aggressive types in particular (13, 14) . On this background, PI3Kinase inhibitors are promising drugs presently entering clinical trials (15) .
In a standard clinical setting, immunohistochemical markers would be more applicable than estimation of PI3Kinase activation in fresh tissues. Stathmin overexpression has been shown to be associated with PI3Kinase activation in breast (9) and endometrial cancers (8) , indicating that Stathmin staining may have a potential as a marker to select patients more likely to respond to treatment with PI3Kinase inhibitors.
To our knowledge, this is the first study to validate in a large, prospective multicentre setting the value of immunohistochemical staining of Stathmin. In addition to prognostic
Research. in the majority of cases (763: 71%). The decision was made by the responsible surgeon, based on an overall assessment of the patient's risk of recurrence balanced by the general comorbidity. 101 patients died of endometrial cancer. For further patient characteristics see Table 1 .
Tissue microarray (TMA)
Hematoxylin and eosin stained slides from individual hysterectomy and curettage specimen were evaluated to identify the area with representative tissue of highest tumor grade. Three 0.6 mm tissue cylinders from the selected area of each specimen were punched out and mounted in a recipient paraffin block using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA). This method for producing tissue microarrays (TMA) has been described and validated before (17, 18) . Representative TMAs for immunohistochemical staining for Stathmin were available from 477 hysterectomy (Haukeland University Hospital only) and 818 curettage specimens (multicenter setting).
TMA sections of 5μm were dewaxed with xylene/ethanol for immunohistochemical staining. Substituting the primary antibody with diluent only was used as negative control.
Immunohistochemistry

Evaluation of staining
Blinded for patient characteristics and outcome, the slides were evaluated by one of the authors (J.T.) using a standard light microscope. A semi-quantitative grading system incorporating staining intensity (score 0-3) and area of tumor with positive staining (0= no staining, 1=<10%, 2=10-50% and 3=>50% of tumor cells) was applied. Staining index was calculated as the product of staining intensity and staining area, range 0-9, as described in several publications (19, 20) . Values defined by the upper quartile for the data set were considered positive.
Images for illustration were captured using a Leica DC300 digital camera with a 40 x magnification lens.
Statistical analysis
Statistics were performed by the statistical program SPSS15.0. Associations between categorical variables were evaluated by Pearson's chi-square test. P-values represent 2-sided tests and are considered of statistical significance when p<0.05. Univariate analyses of time to recurrence (recurrence-free survival) and death due to endometrial carcinoma (diseasespecific survival) were performed using the Kaplan-Meier method and differences were estimated by the Mantel-Cox (log-rank) test. Binary logistic regression was used to evaluate the odds ratios (OR) for lymph node metastasis. Cox' proportional hazards method were used for multivariate survival analyses.
Power calculation
Research. Stathmin overexpression in aggressive endometrial cancer -9 -Estimation of sample size was done by chi-square test using software East4, 2005 Cytel Software Corp. To achieve 90% power to detect a 20% higher occurrence of positive markers in patients with metastatic lymph nodes (25% versus 5%) at a 5% significance level, 101 patients was needed for inclusion. With an estimated prevalence for lymph node metastases of 20%, 500 cases should be included to achieve sufficient power. In order to reach 90 % power detecting 30% difference in 5-year survival (90 % for patients with negative marker versus 60% with positive marker) at a 5% level of significance, 65 patients were needed; assuming the positive to negative ratio for the marker was 1:3.
Approvals and grant support
The study has been approved by the Norwegian Data Inspectorate (961478-2), the (Table 3) .
Results
Stathmin expression and clinico-pathological features
Multivariate survival analyses
Disease-specific survival was significantly related to age, menopausal status, FIGO stage, histological subtype and grade, ploidy and lymph node status in univariate analyses (Table 4) 
Discussion
The protein expression of Stathmin has been explored and found to correlate to clinico-pathological factors and poor prognosis in several cancers in different tissues such as brain (21), oral mucosa (22) , breast (9, 10, 23), urothelial (24) as well as ovarian (11) and uterine cervix (12) . Recently, Stathmin has been identified as a marker for PI3CA signaling pathway activation and poor prognosis also in endometrial carcinomas (8) . In the present study, we validate the applicability of immunohistochemical staining for Stathmin as a marker applied in a prospective, multicentre setting to detect endometrial cancer patients with an aggressive phenotype.
In endometrial carcinoma, the tumor is easily accessible for biopsy by curettage prior to primary surgical treatment. Parameters routinely investigated in curettage specimens, such as histologic type and grade, yield prognostic information relevant for the planned surgical procedure. Still, relatively poor correlation between curettage and hysterectomy findings has motivated the search for improved measures to define high and low risk patients (25) . survival benefit for lymph node sampling (4, 5) . Depth of myometrial tumor infiltration, histologic type and grade in hysterectomy specimen can predict lymph node spread (2, 30) , and different algorithms have been explored in the process for optimal selection of patients for sampling (31) . Unfortunately, such assessment pre-and perioperatively have been less reliable than these assessment in hysterectomy specimen (25, 32) , indicating that they are suboptimal as guidance regarding the need for lymph node sampling. Only few studies have investigated curettage markers for lymph node metastases adjusted for standard preoperative risk assessment based on histopathologic evaluation of curettage. Mariani et al. (33) reported p53 as an independent predictor of lymph node metastasis. The present study identifying Stathmin expression in curettage as an independent predictor for lymph node metastases is, to the best of our knowledge, the first of its kind, and is also a large prospective multicenter trial.
From clinical trials of targeted therapies in breast, lung and colorectal cancer we have learned that biomarkers should be applied to design future clinical trials (34) (35, 36) .
Endometrial cancers are heterogeneous in clinical presentation, histopathologic features and molecular characteristics (8) . Ignoring this diversity by sticking to the 'one-size-fits-all' approach in future design of clinical trials, may prevent us from realizing the potential of targeted therapies in management of endometrial cancers.
Taxane is one of the main chemotherapeutics applied in metastatic endometrial carcinoma (37) . Taxane induces polymerization of tubules and stabilization of microtubules and thereby hinder mitosis (38) . It is shown that Stathmin overexpression in breast cancer cell lines promotes Taxane resistance (7). When Stathmin expression was blocked, the Taxane resistance was opposed (39) . For ovarian cancer patients, strong Stathmin expression has been linked to worse survival for patients who received Taxane in combination with Platinum, in contrast to what was seen for patients treated with Platinum alone (11 
Stathmin overexpression in aggressive endometrial cancer -13 -potential for Stathmin expression as a predictive marker for Taxane response in endometrial cancer needs to be explored.
The PIK3Kinase/mTOR pathway is often upregulated in endometrial carcinoma (8, 40) , and PIK3Kinase-and mTOR inhibitors are presently entering clinical trials (15) . The fact that activation of this signature has been found to associate with aggressive endometrial cancer and Stathmin overexpression (8) , suggests Stathmin as a potential predictive marker for response. This needs to be evaluated in further clinical testing of drugs targeting the PI3Kinase pathway.
Conclusion
Stathmin immunohistochemical staining identifies endometrial carcinomas with lymph node metastases and poor survival in a large prospective multicentre setting. The value as predictive marker for response to Taxanes and PI3Kinase inhibition, and as a tool to stratify for lymph node sampling remains to be determined. 
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